All News
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon?
With a better understanding of pathophysiology, improved management guidelines, available medications, and a multidisciplinary approach, pregnancy for lupus patients has become more feasible. Despite these improvements, some patients still experience poor outcomes, highlighting the need for biomarkers that can predict these risks. An abstract presented at #EULAR2024 (POS1393) explored this possibility.
Read Article
POS1035 FVC & risk of lung transplant & mortality in #RAILD
50% pts had FVC % predicted decline in ~6.5yrs
2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
Peter Nash drpnash ( View Tweet)
#EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction & regurgitation) was more common in Triple Ab+ vs Non-Triple Ab. We should monitor and consider an echocardiogram for this group of patient @RheumNow https://t.co/VxFUSpjaG1
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow
https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
Dr. John Cush RheumNow ( View Tweet)
📄 You can now read my article on #CardiovascularDisease, #Stroke & #Mortality @RheumNow!
🌟 Featuring 2 cohort studies from @MayoClinic, presented at #EULAR2024
🔗 https://t.co/b639vE5hSA
@MyasoedovaElena
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 OP0193 Watch out, blinatumomab will BiTE! Bi-specific T-cell engagers (BiTEs), kill Bcells by engaging Tcells. In 6 refractory #RA patients (failed 3 x ts/bDMARDs), deep blood & tissue depletion were met, good response. Brief raised temp but no cytokine storm @RheumNow https://t.co/OmxSbTXfZq
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Fascinating - @ndb_org installed an app to measure smartphone usage, and texting less and moving less were associated with more flares.
The pseudo-wearable in our pockets??
#EULAR2024 POS0678 @RheumNow https://t.co/ZA0hd3Q10d
David Liew drdavidliew ( View Tweet)
Is muscle US useful in RA?
100+ pts 1yr followup
BL muscle thickness correlated w/ grip strength improvement
HAQ improv correlated w/ pennation angle vastus lateralis
No diff between muscle morphology & DAS
I'd say it's still easier to US joints!
@RheumNow #EULAR2024 POS1033
Aurelie Najm AurelieRheumo ( View Tweet)
RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses.
Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow https://t.co/8gY9ocLBDp
David Liew drdavidliew ( View Tweet)
If your GCA flares, do you get the same features as you did at diagnosis?
20% of the time it can be new, so keep on doing the checklist!
(also, visual flares uncommon - the power of pred)
#EULAR2024 POS0110 @MayoClinic @MdWarrington @RheumNow https://t.co/hkF8vJT6HI
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2024 POS0390 What impact of regulatory warning on JAK-i on access to therapy? Data from UK BSSR-BR reported 4 in 5 #RA patients would have been considered ‘high-risk’. Of these, 28% had failed ≥3 biologics; so no suitable alternatives. Enormously impacted @RheumNow https://t.co/XeS9qHXSpH
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What psychosocial factors drive treatment outcomes and disease activity for people living with rheumatoid arthritis?
#EULAR2024 POS0309-PARE @DrMiniDey @ElenaNikiUK @RheumNow https://t.co/q0tTLSL044
David Liew drdavidliew ( View Tweet)
Join me on @RheumNow at 6pm this evening here in Vienna to hear about the roundup from today at #EULAR2024
Dr. Antoni Chan synovialjoints ( View Tweet)
Do we give enough attention to pts mental health?
2 cohort 400+ RA tREACH & DEPAR 500+ PsA
RA 20% depression 30% anxiety
PsA 19% depression 22% anxiety
2 yrs no remission
RA OR 2.5 depression OR 1.7 anxiety
PsA OR 6.10 depression OR 4.67 anxiety
@RheumNow #EULAR2024 POS0946 https://t.co/ok4HRNJqgY
Aurelie Najm AurelieRheumo ( View Tweet)